Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by topic
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by topic
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are here
Home
Archive
Volume 5, Issue 1
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Responses
Article
metrics
Alerts
PDF
Research Article
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Online download statistics by month:
Online download statistics by month: December 2019 to December 2020
Abstract
Full
Pdf
Dec 2019
2
2
0
Jan 2020
5
5
0
Feb 2020
16
16
5
Mar 2020
33
33
2
Apr 2020
37
37
2
May 2020
49
49
12
Jun 2020
29
29
2
Jul 2020
30
31
3
Aug 2020
15
15
9
Sep 2020
33
33
2
Oct 2020
38
38
10
Nov 2020
95
95
1
Dec 2020
13
13
1
Total
395
396
49
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF